Name: ISM - The Future of Sweets
Start: 2011-01-30T00:00:00
End: 0001-01-01T00:00:00
Location: Cologne, Germany

Industry news
Industry news
All news
Business
Food ingredients
New product development
Packaging & processing
Personal care & cosmetics
Policy & regulation
Research & science
Tech & innovation
Must read
Natural alternative to anti-obesity medication linked to weight loss and improved gut health
Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth
Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty
Category news
Category news
Animal nutrition
Bone & joint health
Brain & mental health
Child nutrition
Delivery formats
Food security
Gut health
Heart health
Immunity
Infant nutrition
Men's health
Nutraceuticals
Oral & eye health
Personalized nutrition
Skin & beauty
Sports nutrition
Supplements
Weight management
Women's health
Reports
Reports
Key interviews
Special reports
Technical papers
Must read
Natural alternative to anti-obesity medication linked to weight loss and improved gut health
Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth
Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty
Key trends
Key trends
All key trends
Trend analysis
Nutrition focus
Product innovation
Must read
Natural alternative to anti-obesity medication linked to weight loss and improved gut health
Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth
Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty
Multimedia
Multimedia
All multimedia
Videos
Webinars
Must read
Natural alternative to anti-obesity medication linked to weight loss and improved gut health
Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth
Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty
Publication
Publication
The world of food ingredients
Advertising options
Subscribe now
Editorial enquiries
Must read
Natural alternative to anti-obesity medication linked to weight loss and improved gut health
Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth
Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty
Events
Events
Event listing
Event previews
Event reviews
Must read
Natural alternative to anti-obesity medication linked to weight loss and improved gut health
Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth
Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty
Suppliers
Suppliers
Supplier profiles
Must read
Natural alternative to anti-obesity medication linked to weight loss and improved gut health
Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth
Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty

New product development

Packaging & processing

Personal care & cosmetics

Policy & regulation

Research & science

Tech & innovation

Must read

Natural alternative to anti-obesity medication linked to weight loss and improved gut health

Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth

Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty

Category news

Animal nutrition

Bone & joint health

Brain & mental health

Personalized nutrition

Must read

Natural alternative to anti-obesity medication linked to weight loss and improved gut health

Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth

Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty

Must read

Natural alternative to anti-obesity medication linked to weight loss and improved gut health

Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth

Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty

Must read

Natural alternative to anti-obesity medication linked to weight loss and improved gut health

Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth

Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty

Publication

The world of food ingredients

Advertising options

Editorial enquiries

Must read

Natural alternative to anti-obesity medication linked to weight loss and improved gut health

Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth

Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty

Must read

Natural alternative to anti-obesity medication linked to weight loss and improved gut health

Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth

Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty

Suppliers

Supplier profiles

Must read

Natural alternative to anti-obesity medication linked to weight loss and improved gut health

Oobli gets FDA approval for sweet protein Monellin and expands board to boost growth

Biden’s GLP-1 expansion plan to cut costs and expand access faces Trump uncertainty

Home EventsISM - The Future of Sweets

ISM - The Future of Sweets

Date

30 Jan - 2 Feb, 2010

Location

Cologne, Germany

Organizer

Koeln Messe

c.majchrowicz@koelnmesse.de

Website

http://www.ism-cologne.com/en/ism/home/index.php

Subscribe to our newsletters

PlatformsFood Ingredients FirstNutrition InsightPackaging InsightsPersonal Care InsightsThe World of Food Ingredients

About usContact usAdvertisingPrivacy statementSitemap